Increased apolipoprotein AI production rate and redistribution of high-density lipoprotein size induced by estrogen plus progestin as oral contraceptive

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 4891-4897

  Duvillard, Laurence ^a   Dautin, Guillaume ^a   Florentin, Emmanuel ^a   Jeannin, Aline ^a   De Barros, Jean Paul Pais ^a   Lagrost, Laurent ^a   Petit, Jean Michel ^a,b   Gambert, Philippe ^a   Vergès, Bruno ^a,b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CARBON 13; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GESTODENE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUCINE; LOW DENSITY LIPOPROTEIN; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CATABOLISM; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 73249129285     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1402     Document Type: Article

References (37)

1. Movva R, Rader DJ 2008 Laboratory assessment of HDL heterogeneity and function. Clin Chem 54:788-800
2. Wilson PW, Abbott RD, Castelli WP 1988 High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8:737-741
3. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE 2005 Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294:326-333
4. Talmud PJ, Hawe E, Miller GJ, Humphries SE 2002 Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 22:1918-1923
5. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E 2001 High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:2026-2033
6. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ 2008 High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51:634-642
7. Gotto Jr AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS 2000 Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101:477-484
8. Jessup W, Gelissen IC, Gaus K, Kritharides L 2006 Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 17:247-257
9. Curtiss LK, Valenta DT, Hime NJ, Rye KA 2006 What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol 26:12-19
10. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, Stocker R 1998 Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by α-tocopherol. J Biol Chem 273:6080-6087
11. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM 2000 Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41:1481-1494
12. Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW 2001 Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 276:24473-24481
13. Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H 1998 Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception 58:83-91
14. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V 1990 The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375-1381
15. Sulak P, Lippman J, Siu C, Massaro J, Godwin A 1999 Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction. Contraception 59:161-166
16. Fotherby K 1995 Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 51:3-12
17. Scharnagl H, Petersen G, Nauck M, Teichmann AT, Wieland H, März W 2004 Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinyl estradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 69:105-113
18. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer Jr HB, Levy RI 1983 The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57:262-267
19. Lamon-Fava S, Postfai B, Diffenderfer M, DeLuca C, O'Connor Jr J, Welty FK, Dolnikowski GG, Barrett PH, Schaefer EJ 2006 Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women. Arterioscler Thromb Vasc Biol 26:385-391
20. Brinton EA 1996 Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol 16:431-440
21. Walsh BW, Li H, Sacks FM 1994 Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 35:2083-2093
22. Pont F, Duvillard L, Florentin E, Gambert P, Vergès B 2002 High-density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int J Obes Relat Metab Disord 26:1151-1158
23. Duvillard L, Pont F, Florentin E, Gambert P, Vergès B 2000 Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 152:229-237
24. Pont F, Duvillard L, Vergès B, Gambert P 1998 Development of compartmental models in stable isotope experiments: application to lipoprotein metabolism. Arterioscl Thromb Vasc Biol 18:853-860
25. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer Jr HB 1993 Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 34:2207-2215
26. Foster DM, Barrett PH, Toffolo G, Beltz WF, Cobelli C 1993 Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J Lipid Res 34:2193-2205
27. De Oliveira E, Silva ER, Foster D, McGee Harper M, Seidman CE, Smith JD, Breslow JL, Brinton EA 2000 Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation 102:2347-2352
28. Lagrost L, Athias A, Herbeth B, Guyard-Dangremont V, Artur Y, Paille F, Gambert P, Lallemant C 1996 Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem 271:19058-19065
29. Winkler UH, Sudik R 2009 The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception 79:15-23
30. Archer TK, Tam SP, Deeley RG 1986 Kinetics of estrogen-dependent modulation of apolipoprotein A-I synthesis in human hepatoma cells. J Biol Chem 261:5067-5074
31. Jin FY, Kamanna VS, Kashyap ML 1998 Estradiol stimulates apolipoprotein A-I- but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells. Arterioscler Thromb Vasc Biol 18:999-1006
32. Harnish DC, Evans MJ, Scicchitano MS, Bhat RA, Karathanasis SK 1998 Estrogen regulation of the apolipoprotein AI gene promoter through transcription cofactor sharing. J Biol Chem 273:9270-9278
33. Tam SP, Archer TK, Deeley RG 1986 Biphasic effects of estrogen on apolipoprotein synthesis in human hepatoma cells: mechanism of antagonism by testosterone. Proc Natl Acad Sci USA 83:3111-3115
34. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R 2003 Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292-2300
35. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA,Guertin MC, Rodés-Cabau J 2007 Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297:1675-1682
36. Kontush A, Chantepie S, Chapman MJ 2003 Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23:1881-1888
37. de Souza JA, Vindis C, Nègre-Salvayre A, Rye KA, Couturier M, Therond P, Chantepie S, Salvayre R, Chapman MJ, Kontush A 20 February 2009 Small, dense HDL3 particles attenuates apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 10.1111/j.1582-4934.2009.00713.x